Blockchain

Forgd is Reinventing Web3 Advisory with Free Tools for Tokenomics Design, Liquidity Monitoring, and Token Cap Table Management

on

    More in Blockchain:

    New York, NY, September 3rd, 2024, Chainwire

    Forgd, a token advisory and optimization platform, announced the launch of its free-to-use web platform, which provides blockchain projects unrestricted access to tools for tokenomics design, liquidity monitoring, cap table management, and financial planning. Forgd eliminates financial barriers associated with traditional Web3 Advisory and consolidates an otherwise fragmented services industry built to support blockchain projects as they issue a token.

    A token launch involves complex challenges, prompting many blockchain projects to hire multiple external advisors for tasks like tokenomics modeling, market maker engagement, and exchange listing. These engagements can be costly and often lead to operational inefficiencies, given that few advisors operate an end-to-end process. Forgd addresses these challenges with free software tools for executing all vital go-to-market activities and optimizing token performance post-launch. This “self-service” approach to Web3 advisory allows teams to execute at their own pace.

    “Many of the tasks involved in a token launch are outside the expertise of a typical tech founder, which is why we created a set of tools to streamline and simplify the process in an end-to-end application,” said Shane Molidor, CEO and Founder of Forgd. “Forgd was built in response to the recurring needs of founders we’ve observed in Web3. Our DIY software tools not only reduce costs but also allow teams to concentrate on product innovation rather than specialized capital market activities.”

    Shane Molidor is a 10-year cryptocurrency veteran who formerly operated as CEO of AscendEX, Head of Trading at FBG Capital, and Business Development Associate at Gemini. Forgd recently enhanced its capabilities by acquiring Tokenomics DAO, a research institution focused on tokenomics and novel protocol design. 

    For blockchain projects that haven’t yet launched their token, Forgd helps them design tokenomics, conduct cash flow analysis & prepare for fundraising, secure partnerships with market makers & exchanges, and navigate administrative tasks such as offshore company formation. For projects with a live token, Forgd provides tools for monitoring market maker performance & token unlocks, automated token streaming, and even non-custodial liquidity provision.

    In a strategic move, Forgd has aligned with the Solana Foundation to provide select tools exclusively for projects built on the Solana blockchain. This collaboration underscores the Forgd commitment to supporting scalable blockchain ecosystems and fostering project growth.

    “We are thrilled to collaborate with the Solana Foundation to offer our tools to Solana’s vibrant developer ecosystem,” said Florian Strauf, CTO of Forgd and Founder of Tokenomics DAO. “This strategic alignment highlights our dedication to creating public goods to support blockchain entrepreneurs, and we look forward to partnering with other blockchain base layers to create comprehensive cross-chain support.”

    Forgd reports that over 250 projects have already benefited from using its pioneering tools, such as “AMM²”, a non-custodial market making protocol that empowers projects to act as their liquidity provider across all major exchanges with automated rebalancing.

    “The positive response since our private beta launch in Q1’24 has been overwhelming,” commented Shane Molidor. “Our team is motivated to continue innovating and developing new tools to empower Web3 entrepreneurs aiming to launch and scale projects of their own.”

    For more information about Forgd and its services, users can visit Forgd.com.

    About Forgd:

    Forgd is a token advisory and optimization platform with free software tools for blockchain founders to launch and scale their projects.

    Operating as a public good, Forgd is reinventing Web3 advisory by providing blockchain projects free access to specialized capital markets tools such as tokenomics modeling, liquidity monitoring, cap table management, exchange listing, and financial planning. In addition to its self-service software tools, Forgd offers tailored consulting services for teams seeking extra guidance. This approach allows Forgd to service a broad spectrum of blockchain projects ranging from DIY enthusiasts to those who prefer white-glove support, ensuring accessibility and expert assistance are readily available.

    www.x.com/forgd_

    Contact

    Marketing
    Dan Mulligan
    Forgd
    dan@forgd.com

    PostAd_coinrule_banner728x90

    Leave a Comment

    Your email address will not be published. Required fields are marked *

    *

    PersonalAIze and Cube Forge Groundbreaking Partnership to Accelerate AI-Driven Healthcare Platform and Point of Care Diagnostics

    2024-09-19T13:00:00Z

    Strategic partnership aims to further develop Cube’s award-winning AI guided platform for Software as a Service (SaaS) for the private sector and large healthcare systems and diagnostic to support clinicians and patients in making informed therapeutic decisions from early detection to personalized treatment and disease monitoring, for improved health outcomes

    AMSTERDAM, Sept. 19, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) PersonalAIze and RenovaroCube are proud to announce a strategic partnership to develop, validate, and commercialize Cube’s AI-driven, multi-omic platform for early detection of cancer and other diseases. This strategic partnership aims to provide services to many AI companies and healthcare systems while also creating the next generation of medical diagnostics through cutting-edge AI by driving greater accuracy, transparency, and trust in healthcare solutions.

    Prof. Mark Hoogendoorn, Co-CEO and Co-Founder PersonalAIze: "The strategic partnership between PersonalAIze and Cube has the potential to provide a transformative leap in healthcare diagnostics, uniting cutting-edge AI with trusted, high-performance capabilities and industry related in-depth expertise.”

    Frank van Asch, Founder and CTO of RenovaroCube,” Together, we are pioneering a future where healthcare outcomes are improved by training models for multiple decisions through the entire health journey, ensuring the right accuracy for therapeutic decisions in every disease stage.”

    The first phase of the collaboration focuses on establishing a strong foundation for the partnership, with PersonalAIze providing critical expertise in the integration of AI into healthcare. It will enhance existing collaborations with Academic and corporate partners and create new ones to build an eco-system to help develop and bring to the market a cutting-edge SaaS model and the next generation highly accurate diagnostics, starting with cancer.

    Prof Sandjai Buhlai, Co-CEO and Co-Founder PersonalAIze: “This collaboration signals a bold step forward in utilizing the full potential of AI potentially to help revolutionize early-stage medical interventions and diagnosis at the earliest stage of cancer before imaging has been able to detect the tumors.”

    Key contributions from PersonalAIze include:

    • Ethical AI: Ensuring the AI models are free from harmful biases and trained to support fairness and inclusivity in medical diagnostics.
    • Legal Guidance: Providing expert advice on legal responsibilities tied to AI outputs, including issues of AI accountability and potential liability.
    • Regulatory Compliance: Assisting in navigating existing and emerging regulations such as NEN, ISO, GDPR, and the AI Act, ensuring the platform adheres to all relevant healthcare regulations and clinical guidelines.
    • Medical and Diagnostic Input: Offering support in clinical validation in collaboration with medical scientists to ensure the AI is reliable and effective in real-world medical environments.
    • Explainable AI: Developing AI models that are transparent, fostering trust and confidence from both healthcare providers and patients.

    Key Resources and Support from PersonalAIze
    As part of the collaboration, PersonalAIze will contribute:

    • Expert Personnel: Including a Principal Investigator (PI) to lead clinical AI efforts, a project manager to coordinate the collaboration and a strategic advisor to oversee the scientific strategy and execution.
    • Research and Talent Capacity: Leveraging academic partnerships to ensure access to cutting-edge research and innovation and facilitating talent scouting to support the project’s development.
    • Academic Spin-Out Opportunities: Supporting the commercialization of academic research through potential spin-out ventures related to AI diagnostics.
    • Co-Development of AI Platform: Jointly developing a science-driven, evidence-based AI platform that meets rigorous clinical and regulatory standards.
    • Ongoing Research and Publications: Contributing to the body of research through support with peer-reviewed publications in collaboration with clinical experts that will help build trust within the medical community and among regulatory bodies.
    • Architecture and Strategy Guidance: Continuously advising on the platform’s architecture and strategic direction, ensuring it stays aligned with the latest industry trends and scientific advancements.
    • Trusted AI: Developing a trustworthy, explainable AI platform that inspires confidence among healthcare providers and patients through clear and transparent decision-making processes.

    About PersonalAIze
    PersonalAIze focuses on building solutions that improve healthcare by leveraging state-of-the-art AI techniques. It has been founded by four experienced professors bringing together decades of research experience in AI and healthcare with the aim to bring the latest scientific AI developments into healthcare practice faster. PersonalAIze does this through both consultancy and product development and targets clinical decision-making systems as well as improvement of health care operations such as capacity planning.

    About Renovaro
    Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.

    RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in disease agnostic decision support.

    Forward-Looking Statements
    Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

    For media inquiries, please contact: karen@renovarocube.com

    Source: Renovaro Inc.


    GlobeNewsWire News

    Recent Comments